JP2013513549A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013513549A5 JP2013513549A5 JP2012527547A JP2012527547A JP2013513549A5 JP 2013513549 A5 JP2013513549 A5 JP 2013513549A5 JP 2012527547 A JP2012527547 A JP 2012527547A JP 2012527547 A JP2012527547 A JP 2012527547A JP 2013513549 A5 JP2013513549 A5 JP 2013513549A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- peptide
- seq
- isolated
- ctl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 229940024606 amino acid Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 4
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 210000001808 exosome Anatomy 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28621309P | 2009-12-14 | 2009-12-14 | |
| US61/286,213 | 2009-12-14 | ||
| US28765009P | 2009-12-17 | 2009-12-17 | |
| US61/287,650 | 2009-12-17 | ||
| US32638010P | 2010-04-21 | 2010-04-21 | |
| US61/326,380 | 2010-04-21 | ||
| PCT/JP2010/007228 WO2011074236A1 (en) | 2009-12-14 | 2010-12-13 | Tmem22 peptides and vaccines including the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013513549A JP2013513549A (ja) | 2013-04-22 |
| JP2013513549A5 true JP2013513549A5 (enExample) | 2014-01-30 |
Family
ID=44167006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527547A Pending JP2013513549A (ja) | 2009-12-14 | 2010-12-13 | Ｔｍｅｍ２２ペプチドおよびそれを含むワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8697631B2 (enExample) |
| EP (1) | EP2513136A4 (enExample) |
| JP (1) | JP2013513549A (enExample) |
| KR (1) | KR20120104350A (enExample) |
| CN (1) | CN102770441A (enExample) |
| AU (1) | AU2010331648A1 (enExample) |
| BR (1) | BR112012014345A2 (enExample) |
| CA (1) | CA2782977A1 (enExample) |
| IL (1) | IL220146A0 (enExample) |
| MX (1) | MX2012006770A (enExample) |
| RU (1) | RU2012130015A (enExample) |
| SG (2) | SG181530A1 (enExample) |
| TW (1) | TW201136604A (enExample) |
| WO (1) | WO2011074236A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2805989A1 (en) | 2010-07-19 | 2012-01-26 | Yeda Research And Development Co. Ltd. | Peptides based on the transmembrane domain of a toll-like receptor (tlr) for treatment of tlr-mediated diseases |
| EP2766384B1 (en) * | 2011-10-10 | 2016-11-23 | Yeda Research and Development Co. Ltd. | Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response |
| BR112015012234A2 (pt) * | 2012-12-04 | 2017-08-15 | Oncotherapy Science Inc | Peptídios sema5b e vacinas contendo os mesmos |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| EP0239102A3 (en) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| EP0841945B1 (en) | 1995-08-03 | 2006-03-08 | Rijksuniversiteit te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6294378B1 (en) | 1996-07-26 | 2001-09-25 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| AU6765098A (en) | 1997-03-19 | 1998-10-12 | Genetics Institute Inc. | Secreted proteins and polynucleotides encoding them |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| ES2294844T3 (es) | 1998-06-25 | 2008-04-01 | Green Peptide Co., Ltd. | Peptidos antigenicos tumorales derivados de ciclofilina b. |
| CA2440773A1 (en) | 2001-03-14 | 2002-09-19 | Dakocytomation Denmark A/S | Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules |
| CA2399569A1 (en) | 2001-09-25 | 2003-03-25 | Yusuke Nakamura | Diagnostic markers and drug targets for treatment of cancer |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| CN103073620B (zh) | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| CA2580412A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| WO2007013575A2 (en) | 2005-07-28 | 2007-02-01 | Oncotherapy Science, Inc. | Method for diagnosing and treating renal cell carcinoma |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| JP5984324B2 (ja) | 2005-12-01 | 2016-09-06 | メディカル プログノシス インスティテュート エー／エス | 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用 |
| TW201425333A (zh) | 2007-04-11 | 2014-07-01 | Oncotherapy Science Inc | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 |
| TW200932260A (en) | 2007-11-28 | 2009-08-01 | Oncotherapy Science Inc | STAT3 epitope peptides |
| CA2715501A1 (en) | 2008-02-15 | 2009-09-24 | Pacific Arrow Limited | Blocking the metastasis of cancer cells and the uses of new compounds thereof |
-
2010
- 2010-12-10 TW TW099143200A patent/TW201136604A/zh unknown
- 2010-12-13 AU AU2010331648A patent/AU2010331648A1/en not_active Abandoned
- 2010-12-13 EP EP20100837268 patent/EP2513136A4/en not_active Withdrawn
- 2010-12-13 MX MX2012006770A patent/MX2012006770A/es active IP Right Grant
- 2010-12-13 JP JP2012527547A patent/JP2013513549A/ja active Pending
- 2010-12-13 SG SG2012041471A patent/SG181530A1/en unknown
- 2010-12-13 CA CA2782977A patent/CA2782977A1/en not_active Abandoned
- 2010-12-13 CN CN2010800638296A patent/CN102770441A/zh active Pending
- 2010-12-13 WO PCT/JP2010/007228 patent/WO2011074236A1/en not_active Ceased
- 2010-12-13 BR BR112012014345A patent/BR112012014345A2/pt not_active IP Right Cessation
- 2010-12-13 US US13/515,656 patent/US8697631B2/en not_active Expired - Fee Related
- 2010-12-13 RU RU2012130015/10A patent/RU2012130015A/ru not_active Application Discontinuation
- 2010-12-13 KR KR1020127018341A patent/KR20120104350A/ko not_active Withdrawn
- 2010-12-13 SG SG10201408245WA patent/SG10201408245WA/en unknown
-
2012
- 2012-06-04 IL IL220146A patent/IL220146A0/en unknown
-
2014
- 2014-03-21 US US14/221,721 patent/US20140199336A1/en not_active Abandoned